You are here:
"M1 - Munich Medicine Alliance" established as a strategic alliance for excellence in healthcare in Munich.
The Helmholtz Pioneer Campus was officially inaugurated today under the slogan "ENGINEERING THE FUTURE OF MEDICINE". Commissioning this new state-of-the-art research facility is a significant milestone for young talents in medical research and…
Prof. Reinhard Zeidler about hope in the fight against glioblastoma, the most common and malignant form of brain tumor and how he accelerates the development of antibodies into application.
Helmholtz Munich and Medigene AG expand their partnership in order to further discover and develop T-cell immunotherapies for solid tumors. Medigene acquired from Helmholtz Munich the exclusive, worldwide rights to the CD40L-CD28 Costimulatory Switch…
Clinical trials are a milestone in the development of safe and effective drugs and therapies. An antibody developed by Helmholtz Munich is now entering a phase 1 clinical trial. Together with the radiopharmaceutical company ITM Isotope Technologies…
Matthias Tschöp, CEO of Helmholtz Munich, talks about translating scientific discoveries into clinical practice, about ambitious targets, and about ideas he acquired during his time in the USA.
We use cookies to improve your experience on our Website. We need cookies to continually improve our services, enable certain features, and when we embed third-party services or content, such as the Vimeo video player. In such cases, information may also be transferred to third parties. By using our website, you agree to the use of cookies. We use different types of cookies. You can personalize your cookie settings here:
